HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Delayed administration of suramin attenuates the progression of renal fibrosis in obstructive nephropathy.

Abstract
We recently showed that suramin treatment prevents the onset of renal fibrosis in a model of obstructive nephropathy induced by unilateral ureteral obstruction (UUO). In this study, we further assessed the effect of delayed administration of suramin on the progression of tubulointerstitial fibrosis. Mice were given a single dose of suramin at 20 mg/kg starting at day 3 of obstruction, and kidneys were harvested after an additional 7 or 14 days of obstruction. Suramin completely blocked further increase in expression of type I collagen and fibronectin and largely suppressed expression of α-smooth muscle actin (α-SMA) in both treatment groups. UUO injury induced phosphorylation of Smad-3, a key mediator of transforming growth factor-β (TGF-β) signaling, epidermal growth factor receptor, and platelet-derived growth factor receptor after 3 days and further increased at 10 days after UUO injury. When suramin was administered at 3 days after obstruction, phosphorylation of these molecules was not further increased in the obstructed kidney. Suramin treatment also inhibited activation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1 and 2, two signaling pathways associated with renal fibrogenesis. Furthermore, delayed application of suramin suppressed TGF-β1-induced expression of α-SMA and fibronectin in cultured renal interstitial fibroblasts. These results indicate that administration of suramin is effective in attenuating the progression of renal fibrosis after injury and suggest the potential clinical application of suramin as an antifibrotic treatment in patients with chronic kidney disease.
AuthorsNa Liu, Evelyn Tolbert, Murugavel Ponnusamy, Haidong Yan, Shougang Zhuang
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 338 Issue 3 Pg. 758-66 (Sep 2011) ISSN: 1521-0103 [Electronic] United States
PMID21622732 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Actins
  • Collagen Type I
  • Fibronectins
  • Smad3 Protein
  • Smad3 protein, mouse
  • Suramin
  • EGFR protein, mouse
  • ErbB Receptors
  • Receptors, Platelet-Derived Growth Factor
  • Extracellular Signal-Regulated MAP Kinases
Topics
  • Actins (metabolism)
  • Animals
  • Blotting, Western
  • Cells, Cultured
  • Collagen Type I (biosynthesis)
  • Disease Progression
  • ErbB Receptors (biosynthesis, genetics)
  • Extracellular Signal-Regulated MAP Kinases (metabolism)
  • Fibroblasts (drug effects, metabolism)
  • Fibronectins (biosynthesis)
  • Fibrosis
  • Immunohistochemistry
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Nephritis, Interstitial (drug therapy, etiology, pathology)
  • Phosphorylation
  • Receptors, Platelet-Derived Growth Factor (biosynthesis, genetics)
  • Smad3 Protein (metabolism)
  • Suramin (therapeutic use)
  • Ureteral Obstruction (complications, drug therapy, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: